
Validea's guru fundamental report rates HIMS & HERS HEALTH INC (HIMS) at 75% using the Motley Fool Small-Cap Growth Investor model, placing it below the 80% threshold typically indicating investor interest. While HIMS passed numerous fundamental criteria including profit margin and cash flow, it failed on critical metrics such as year-over-year sales and EPS growth, the 'Fool Ratio' (P/E to Growth), and daily dollar volume, contributing to its sub-threshold score.
According to Validea's fundamental report, Hims & Hers Health Inc. (HIMS) scores a 75% using the Motley Fool Small-Cap Growth Investor model, placing it below the 80% threshold that typically indicates strategist interest. The analysis reveals a company with a bifurcated profile. On one hand, HIMS demonstrates solid underlying fundamentals, passing criteria for profit margin consistency, cash flow from operations, significant insider holdings, and a strong balance sheet indicated by its cash position and low long-term debt-to-equity ratio. On the other hand, the model highlights critical weaknesses for a growth-oriented investment thesis. HIMS failed key tests including year-over-year sales and EPS growth comparisons, suggesting a potential deceleration. This growth concern is further compounded by a failure on the 'Fool Ratio' (a P/E to growth metric), implying its valuation may be stretched relative to its growth prospects. Additionally, the stock failed screens for its absolute sales level and daily dollar volume, which could be a liquidity concern for larger institutional investors.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment